Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alphapharm's Attempt To Force Listing of Celexa Patent Rejected By Court

This article was originally published in The Pink Sheet Daily

Executive Summary

Federal judge affirms FDA's "ministerial" role in declining to list certain patents in the "Orange Book." Forest said the patent should not be listed because it claims an intermediate of citalopram.

You may also be interested in...

Orange Book Policing May Increase, US FDA's Gottlieb Says

Commissioner says agency will modernize drug patent reference manual this year and consider potential changes to Orange Book administration policy. However, any transformative moves could trigger a court challenge.

Lexapro SSRI Switch Plan On Target Despite Slower Than Expected Decline In Celexa Sales

Forest attributes the majority of Celexa’s $15.4 mil. sequential quarterly sales growth to a 4% price increase taken in March. Forest’s estimates put the Celexa revenue run rate in early 2005 at $680 mil., above earlier predictions.

Forest Expects Multiple Celexa Generics To Enter Market In January

Company sees "no impediments" to ANDA approvals for antidepressant, beyond demands on FDA resources to review multiple applications simultaneously. Forest believes the agency will try to approve all generics simultaneously, making it difficult to complete the reviews before the end of the year.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts